Challenges in the treatment of dysthymia: a narrative review

References

• Akiskal HS, Cassano GB. Dysthymia and the spectrum of chronic depression. New York (NY): The Guilford Press; 1997.
   Google Scholar
• Ventriglio A, Bhugra D, Sampogna G, et al. From dysthymia to treatment-resistant depression: evolution of a psychopathological construct. Int Rev Psych. 2020;32(5–6): 471–476. doi: 10.1080/09540261.2020.1765517
   Google Scholar
• Berrios G, Porter RA. A history of clinical Psychiatry: the origin and history of psychiatric disorders. London: Athlone; 1995.
   Google Scholar
• Michel B. History of depression through the ages. Arch Depress Anxiety. 2020;6(1):010–018. doi: 10.17352/2455-5460.000045
   Google Scholar
• Brieger P, Marneros A. Dysthymia and cyclothymia: historical origins and contemporary development. J Affect Disord. 1997;45(3):117–126. doi: 10.1016/S0165-0327(97)00053-0
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association Washington DC. Diagnostic and statistical manual of mental disorders. 2nd ed. (WA): American Psychiatric Association Washington DC; 1968.
   Google Scholar
• Judd LL, Schettler PJ, Akiskal HS. The prevalence, clinical relevance, and public health significance of subthreshold depressions. Psychiatr Clin North Am. 2002 Dec;25(4):685–698. doi: 10.1016/S0193-953X(02)00026-6
   PubMed Web of Science ®Google Scholar
• Akiskal HS. Dysthymia and cyclothymia in psychiatric practice a century after Kraepelin. J Affect Disord. 2001;62(1–2):17–31. doi: 10.1016/S0165-0327(00)00347-5
   PubMed Web of Science ®Google Scholar
• Horwath E, Johnson J, Klerman GL, et al. Depressive symptoms as relative and attributable risk factors for first-onset major depression. Arch Gen Psychiatry. 1992;49(10):817. doi: 10.1001/archpsyc.1992.01820100061011
   PubMed Web of Science ®Google Scholar
• Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 1978;35(6):773–782. doi: 10.1001/archpsyc.1978.01770300115013
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Whashington (DC): American Psychiatric Press; 1980.
   Google Scholar
• Akiskal HS, Rosenthal TL, Haykal RF, et al. Characterological depressions clinical and sleep eeg findings separating “subaffective dysthymias” from “character spectrum disorders”. Arch Gen Psychiatry. 1980;37(7):777–783. doi: 10.1001/archpsyc.1980.01780200055006
   PubMed Web of Science ®Google Scholar
• Akiskal HS, Bitar AH, Puzantian VR, et al. The nosological status of neurotic depression: a prospective three- to four-year follow-up examination in light of the primary-secondary and unipolar-bipolar dichotomies. Arch Gen Psychiatry. 1978;35(6):756–766. doi: 10.1001/archpsyc.1978.01770300098011
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Whashington (DC): American Psychiatric Press; 1987.
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. Washington (DC): American Psychiatric Association; 1994.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Association; 2000.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): American Psychiatric Association; 2013.
   Google Scholar
• Klein DN, Riso LP, Anderson RL. DSM-III-R dysthymia: antecedents and underlying assumptions. Prog Exp Pers Psychopathol Res. 1993;16:222–253.
   PubMedGoogle Scholar
• Keller MB, Harrison W, Fawcett JA, et al. Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. Psychopharmacol Bull. 1995;31(2):205–212.
   PubMedGoogle Scholar
• Keller MB, Shapiro RW. “Double Depression”: Superimposition of acute depressive episodes on chronic depressive disorders. Am J Psychiatry. 1982;139(4):439–442.
   Web of Science ®Google Scholar
• Kocsis JH, Frances AJ. A critical discussion of DSM-III dysthymic disorder. Am J Psychiatry. 1987;144(12):1534–1542.
   PubMed Web of Science ®Google Scholar
• Klein DN, Riso LP, Donaldson SK, et al. Family study of early-onset dysthymia. Mood and personality disorders in relatives of outpatients with dysthymia and episodic major depression and normal controls. Arch Gen Psychiatry. 1995;52(6):487–496. doi: 10.1001/archpsyc.1995.03950180073010
   PubMed Web of Science ®Google Scholar
• Rhebergen D, Beekman AT, de GR, et al. The three-year naturalistic course of major depressive disorder, dysthymic disorder and double depression. Journal Of Affective Disorders. 2009;115(3):450–459. doi: 10.1016/j.jad.2008.10.018
   PubMed Web of Science ®Google Scholar
• Pepper CM, Klein DN, Anderson RL, et al. DSM-III-R axis II comorbidity in dysthymia and major depression. Am J Psychiatry. 1995;152:239–247.
   PubMed Web of Science ®Google Scholar
• Riso LP, Klein DN, Ferro T, et al. Understanding the comorbidity between early-onset dysthymia and cluster B personality disorders: a family study. Am J Psychiatry. 1996;153(7):900–906.
   PubMed Web of Science ®Google Scholar
• Klein DN, Shankman SA, Lewinsohn PM, et al. Family study of chronic depression in a community sample of young adults. Am J Psychiatry. 2004;161(4):646–653. doi: 10.1176/appi.ajp.161.4.646
   PubMed Web of Science ®Google Scholar
• Holmstrand C, Engström G, Träskman-Bendz L. Disentangling dysthymia from major depressive disorder in suicide attempters’ suicidality, comorbidity and symptomatology. Nord J Psychiatry. 2008;62(1):25–31. doi: 10.1080/08039480801960164
   PubMed Web of Science ®Google Scholar
• Klein DN, Schwartz JE, Rose S, et al. Five-year course and outcome of dysthymic disorder: a prospective, naturalistic follow-up study. American Journal Of Psychiatry. 2000;157(6):931–939. doi: 10.1176/appi.ajp.157.6.931
   PubMed Web of Science ®Google Scholar
• Brunello N, Akiskal H, Boyer P, et al. Dysthymia: clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas. J Affect Disord. 1999;52(1–3):275–290. doi: 10.1016/S0165-0327(98)00163-3
   PubMed Web of Science ®Google Scholar
• Klein DN, Schatzberg AF, Mccullough JP, et al. Early-versus late-onset dysthymic disorder: comparison in out-patients with superimposed major depressive episodes. J Affect Disord. 1999;52(1–3):187–196. doi: 10.1016/S0165-0327(98)00079-2
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62(6):593. doi: 10.1001/archpsyc.62.6.593
   PubMed Web of Science ®Google Scholar
• Hellerstein DJ, Agosti V, Bosi M, et al. Impairment in psychosocial functioning associated with dysthymic disorder in the NESARC study. J Affect Disord. 2010;127(1–3):84–88. doi: 10.1016/j.jad.2010.04.013
   PubMed Web of Science ®Google Scholar
• Dougherty LR, Klein DN, Davila J. A growth curve analysis of the course of dysthymic disorder: the effects of chronic stress and moderation by adverse parent-child relationships and family history. J Consult Clin Psychol. 2004;72(6):1012–1021. doi: 10.1037/0022-006X.72.6.1012
   PubMed Web of Science ®Google Scholar
• Stravynski A, Shahar A, Verreault R. A pilot study of the cognitive treatment of dysthymic disorder. Behav Cogn Psychother. 1991;19(4):369–372. doi: 10.1017/S0141347300014063
   Google Scholar
• Boyer P, Lecrubier Y, Stalla-Bourdillon A, et al. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology. 1999;39(1):25–32. doi: 10.1159/000026556
   PubMed Web of Science ®Google Scholar
• Hellerstein DJ, Yanowitch P, Rosenthal J, et al. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry. 1993;150:1169–1175.
   PubMed Web of Science ®Google Scholar
• Ravindran AV, Anisman H, Merali Z, et al. Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairments. Ajp. 1999;156(10):1608–1617. doi: 10.1176/ajp.156.10.1608
   Google Scholar
• Hellerstein DJ, Little SAS, Wallner Samstag L, et al. Adding group psychotherapy to medication treatment in dysthymia. J Psychother Pract Res. 2001;10(2):93–103.
   PubMedGoogle Scholar
• Devanand DP. Dysthymic disorder in the elderly population. Int Psychogeriatr. 2014;26(1):39–48. doi: 10.1017/S104161021300166X
   PubMed Web of Science ®Google Scholar
• Markowitz JC, Kocsis JH, Bleiberg KL, et al. A comparative trial of psychotherapy and pharmacotherapy for “pure” dysthymic patients. J Affect Disord. 2005;89(1–3):167–175. doi: 10.1016/j.jad.2005.10.001
   PubMed Web of Science ®Google Scholar
• Hellerstein DJ, Batchelder ST, Hyler S, et al. Escitalopram versus placebo in the treatment of dysthymic disorder. Int Clin Psychopharmacol. 2010;25(3):143–148. doi: 10.1097/YIC.0b013e328333c35e
   PubMed Web of Science ®Google Scholar
• Vanelle J-M, Attar-Levy D, Poirier M-F, et al. Controlled efficacy study of fluoxetine in dysthymia. Br J Psychiatry. 1997;170(4):345–350. doi: 10.1192/bjp.170.4.345
   PubMedGoogle Scholar
• Dursun SM, Bird D, Ronson KE. Nefazodone treatment of dysthymic disorder an open, long-term, prospective pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(4):671–676. doi: 10.1016/S0278-5846(01)00316-5
   PubMed Web of Science ®Google Scholar
• Rocca P, Marchiaro L, Rasetti R, et al. A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes. Psychiatry Res. 2002;112(2):145–152. doi: 10.1016/S0165-1781(02)00188-9
   PubMed Web of Science ®Google Scholar
• McCullough JP. Psychotherapy for dysthymia. A naturalistic study of ten patients. J Nerv Ment Dis. 1991;179(12):734–740. doi: 10.1097/00005053-199112000-00004
   PubMed Web of Science ®Google Scholar
• Ravindran AV, Bialik RJ, Lapierre YD. Therapeutic efficacy of specific serotonin reuptake inhibitors (SSRIs) in dysthymia. Can J Psychiatry. 1994;39(1):21–26. doi: 10.1177/070674379403900106
   PubMed Web of Science ®Google Scholar
• Otero FJ, Hernandez-Herrero C, Martinez-Arevalo M-J, et al. Fluoxetine/bentazepam combination in the treatment of dysthymic disorders. Curr Ther Res. 1994;55(5):519–531. doi: 10.1016/S0011-393X(05)80182-1
   Web of Science ®Google Scholar
• Serrano-Blanco A, Gabarron E, Garcia-Bayo I, et al. Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine. J Affect Disord. 2006;91(2–3):153–163. doi: 10.1016/j.jad.2005.11.014
   PubMed Web of Science ®Google Scholar
• Bersani G, Meco G, Denaro A, et al. L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. Eur Neuropsychopharmacol. 2013;23(10):1219–1225. doi: 10.1016/j.euroneuro.2012.11.013
   PubMed Web of Science ®Google Scholar
• Thase ME, Rosenbaum J, Fava M, et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry. 1996;53(9):777. doi: 10.1001/archpsyc.1996.01830090023004
   PubMed Web of Science ®Google Scholar
• Anisman H, Ravindran AV, Griffiths J, et al. Interleukin-1β production in dysthymia before and after pharmacotherapy. Biol Psychiatry. 1999;46:1649–1655. doi: 10.1016/S0006-3223(99)00211-5
   PubMed Web of Science ®Google Scholar
• Ravindran AV, Guelfi JD, Lane RM, et al. Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. J Clin Psychiatry. 2000;61:821–827. doi: 10.4088/JCP.v61n1103
   PubMed Web of Science ®Google Scholar
• Bakish D, Lapierre YD, Weinstein R, et al. Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder. J Clin Psychopharmacol. 1993;13(6):409–414. doi: 10.1097/00004714-199312000-00006
   PubMed Web of Science ®Google Scholar
• Salzmann E, Robin JL. Multicentric double-blind study comparing efficacy and safety of minaprine and imipramine in dysthymic disorders. Neuropsychobiology. 1995;31(2):68–75. doi: 10.1159/000119175
   PubMed Web of Science ®Google Scholar
• Versiani M, Amrein R, Stabl M. Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International collaborative study group. International Clinical Psychopharmacology. 1997;12(4):183–194. doi: 10.1097/00004850-199707000-00001
   PubMed Web of Science ®Google Scholar
• Reyntjens A, Gelders YG, Hoppenbrouwers MJA, et al. Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin-S 2 receptor blocker. Drug Development Research. 1986;8(1–4):205–211. doi: 10.1002/ddr.430080124
   Web of Science ®Google Scholar
• Geisler A, Mygind S, Knudsen OR, et al. Ritanserin and flupenthixol in dysthymic disorder: A controlled double-blind study in general practice. Nord J Psychiatry. 1992;46(4):237–243. doi: 10.3109/08039489209099694
   Google Scholar
• Rocca P, Fonzo V, Ravizza L, et al. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J Affect Disord. 2002;70(3):313–317. doi: 10.1016/S0165-0327(01)00327-5
   PubMed Web of Science ®Google Scholar
• Devanand DP, Nobler MS, Cheng J, et al. Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder. Am J Geriatric Psychiatry. 2005;13(1):59–68. doi: 10.1097/00019442-200501000-00009
   PubMed Web of Science ®Google Scholar
• Ravindran AV, Cameron C, Bhatla R, et al. Paroxetine in the treatment of dysthymic disorder without co-morbidities: A double-blind, placebo-controlled, flexible-dose study. Asian J Psychiatr. 2013;6(2):157–161. doi: 10.1016/j.ajp.2012.10.004
   PubMedGoogle Scholar
• McCullough JP. Cognitive-behavioral analysis system of psychotherapy: an interactional treatment approach for dysthymic disorder. Psychiatry. 1984;47(3):234–250. doi: 10.1080/00332747.1984.11024245
   PubMed Web of Science ®Google Scholar
• Marin DB, Kocsis JH, Parides M. Desipramine for the treatment of “pure” dysthymia versus “double” depression. Am J Psychiatry. 1994;151:1079–1080.
   PubMed Web of Science ®Google Scholar
• Friedman RA, Markowitz JC, Parides M, et al. Acute response of social functioning in dysthymic patients with desipramine. Journal Of Affective Disorders. 1995;34(2):85–88. doi: 10.1016/0165-0327(95)00003-6
   PubMed Web of Science ®Google Scholar
• Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission a double-blind, comparative study. J Affect Disord. 1998;48(1):47–56. doi: 10.1016/S0165-0327(97)00139-0
   PubMed Web of Science ®Google Scholar
• de Mello MF, Myczcowisk LM, Menezes PR. A randomized controlled trial comparing moclobemide and moclobemide plus interpersonal psychotherapy in the treatment of dysthymic disorder. J Psychother Pract Res. 2001 Spring;10(2):117–23.
   Google Scholar
• Hellerstein DJ, Yanowitch P, Rosenthal J, et al. Long-term treatment of double depression: a preliminary study with serotonergic antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18(1):139–147. doi: 10.1016/0278-5846(94)90030-2
   PubMed Web of Science ®Google Scholar
• Lecrubier Y, Boyer P, Turjanski S, et al. Amisulpride Study Group: Amisulpride versus imipramine and placebo in dysthymia and major depression. J Affect Disord. 1997;43:95103.
   Web of Science ®Google Scholar
• Dunner DL, Schmaling KB, Hendrickson H, et al. Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder. Depression. 1996;4(1):34–41. doi: 10.1002/(SICI)1522-7162(1996)4:1<34:AID-DEPR4>3.0.CO;2-F
   PubMedGoogle Scholar
• Williams JJ, Barrett J, Oxman T, et al. Treatment of dysthymia and minor depression in primary care a randomized controlled trial in older adults. JAMA. 2000;284(12):1519–1526. doi: 10.1001/jama.284.12.1519
   PubMed Web of Science ®Google Scholar
• Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression randomized controlled trial. JAMA. 1998;280(19):1665–1672. doi: 10.1001/jama.280.19.1665
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ, Trivedi MH, Rush AJ, et al. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry. 2003;54(8):806–817. doi: 10.1016/S0006-3223(02)01971-6
   PubMed Web of Science ®Google Scholar
• Emmelkamp J, Kooistra L, Van Oppen P, et al. Long-term outcome of treatment for persistent depressive disorder: a naturalistic follow-up study. Psychother Psychosom. 2020;89(1):54–55. doi: 10.1159/000503115
   PubMed Web of Science ®Google Scholar
• Koran LM, Gelenberg AJ, Kornstein SG, et al. Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord. 2001;65(1):27–36. doi: 10.1016/S0165-0327(00)00272-X
   PubMed Web of Science ®Google Scholar
• Schramm E, Schneider D, Zobel I, et al. Efficacy of interpersonal psychotherapy plus pharmacotherapy in chronically depressed inpatients. J Affect Disord. 2008;109(1–2):65–73. doi: 10.1016/j.jad.2007.10.013
   PubMed Web of Science ®Google Scholar
• Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000;342(20):1462–1470. doi: 10.1056/NEJM200005183422001
   PubMed Web of Science ®Google Scholar
• Furukawa TA, Schramm E, Weitz ES, et al. Cognitive-Behavioural Analysis System of Psychotherapy (CBASP), a drug, or their combination: differential therapeutics for persistent depressive disorder: a study protocol of an individual participant data network meta-analysis. Psychother Psychosom. 2018;87(3):140–153. doi: 10.1159/000489227
   PubMedGoogle Scholar
• Hellerstein DJ, Hunnicutt-Ferguson K, Stewart JW, et al. Do social functioning and symptoms improve with continuation antidepressant treatment of persistent depressive disorder?An observational study. J Affect Disord. 2017;210:258–264. doi: 10.1016/j.jad.2016.12.026
   PubMed Web of Science ®Google Scholar
• Kocsis JH, Gelenberg AJ, Rothbaum BO, et al. Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression The REVAMP trial augmentation with CBASP and BSP for depression. Arch Gen Psychiatry. 2009;66(11):1178–1188. doi: 10.1001/archgenpsychiatry.2009.144
   PubMed Web of Science ®Google Scholar
• Quagliato LA, Primavera D, Fornaro M, et al. An update on the pharmacotherapeutic strategies for the treatment of dysthymic disorder: a systematic review. Expert Opin Pharmacother. 2023;24(18):2035–2040. Taylor and Francis Ltd
   PubMed Web of Science ®Google Scholar
• Hellerstein DJ, Batchelder ST, Lee A, et al. Rating dysthymia: an assessment of the construct and content validity of the Cornell dysthymia rating scale. J Affect Disord. 2002;71(1–3):85–96. doi: 10.1016/S0165-0327(01)00371-8
   PubMed Web of Science ®Google Scholar
• Schramm E, Klein DN, Elsaesser M, et al. Review of dysthymia and persistent depressive disorder: history, correlates, and clinical implications. Lancet Psychiatry. 2020 sep;7(9):801–812. doi: 10.1016/S2215-0366(20)30099-7
   PubMed Web of Science ®Google Scholar
• Carta MG, Paribello P, Nardi AE, et al. Current pharmacotherapeutic approaches for dysthymic disorder and persistent depressive disorder. Expert Opin Pharmacother. 2019;20(14):1743–1754. doi: 10.1080/14656566.2019.1637419
   PubMed Web of Science ®Google Scholar
• Griffiths J, Ravindran AV, Merali Z, et al. Dysthymia: a review of pharmacological and behavioral factors. Mol Psychiatry. 2000;5(3):242–261. doi: 10.1038/sj.mp.4000697
   PubMed Web of Science ®Google Scholar